简介:摘要:本文规定了开关柜产品技术文件及工艺文件、产品图样中的零部件名称、定义及其编号,同时规定了开关电器设备产品零部件在企业信息管理系统中的编号原则。
简介:【摘要】目的:对异位妊娠患者应用阴道B超与腹部B超诊断的效果进行对比。方法:样本选取在我科住院治疗的,符合纳入和排除标准的异位妊娠患者132例,并分为参照组(采纳腹部B超检查)和观察组(采纳阴道B超检查)各66例,对比两组的效果。结果:就胚芽、附件包块、心血管搏动、宫内假孕囊等相关指标检出率而言,观察组分别为30.30%、93.94%、33.33%以及18.18%,均明显高于参照组的6.06%、63.64%、6.06%、3.03%,有统计学意义(χ2=13.338
简介:摘要:本文主要介绍了内存管理的地址映射和文件管理的混合索引结构。通过一个例子结合了这两部分内容,详细介绍内存访问和外存访问的练习,加深学生对虚拟存储管理的理解。
简介:【摘要】目的:观察对妇产科急腹症患者实施腹部B超与阴道B超联用的诊断价值。方法:从2019年10月至2021年6月择取50例妇产科急腹症患者,所选患者均实施腹部B超检查、阴道B超检查、腹部B超与阴道B超联合检查,对照病理检查结果,分析三种检查方式的诊断结果。结果:经过病理检查,50例患者均确诊,其中30例异位妊娠、12例卵巢囊肿蒂扭转、6例黄体囊肿破裂、2例急性盆腔炎;在腹部B超检查中,38例患者确诊,其中23例异位妊娠、10例卵巢囊肿蒂扭转、4例黄体囊肿破裂、1例急性盆腔炎;在阴道B超检查中,42例患者确诊,其中26例异位妊娠、12例卵巢囊肿蒂扭转、2例黄体囊肿破裂、2例急性盆腔炎;在腹部B超与阴道B超联合检查中,49例患者确诊,其中30例异位妊娠、12例卵巢囊肿蒂扭转、5例黄体囊肿破裂、2例急性盆腔炎;腹部B超与阴道B超联合检查的诊断符合率高于单独腹部B超检查、阴道B超检查,误诊及漏诊率低于单独腹部B超检查、阴道B超检查,P
简介:AbstractBackground:Hepatitis B core-related antigen (HBcrAg) is a promising disease-monitoring marker for chronic hepatitis B (CHB). We investigated correlations between HBcrAg with antiviral efficacy and virological and histological variables.Methods:One hundred and forty-five CHB patients from the mainland of China between August 2013 and September 2016 who underwent liver biopsy received entecavir therapy and had paired liver biopsy at 78 weeks. We analyzed correlations between HBcrAg and virological and histological variables in hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients. We also explored the predictors of HBeAg loss after 78 weeks of antiviral therapy. Pearson correlation analysis and logistic forward stepwise regression were the main statistic methods.Results:HBeAg-positive patients (n = 93) had higher baseline HBcrAg (median 7.4 vs. 5.3 log10 U/mL P < 0.001) and greater HBcrAg declines (median 1.6 vs. 0.9 log10 U/mL P= 0.007) than HBeAg-negative patients after 78 weeks of therapy. At baseline, HBcrAg correlated with hepatitis B virus (HBV) DNA in both HBeAg-positive (r = 0.641, P < 0.001) and -negative patients (r = 0.616, P < 0.001), with hepatitis B surface antigen (HBsAg) in HBeAg-positive patients (r = 0.495, P < 0.001), but not with anti-hepatitis B virus core antibody (anti-HBc). Weak correlations existed between HBcrAg, histology activity index (HAI; r = 0.232, P= 0.025), and Ishak fibrosis score (r= -0.292, P= 0.005) in HBeAg-positive patients. At 78 weeks, significant correlations existed only between HBcrAg and anti-HBc in HBeAg-positive (r = -0.263, P = 0.014) and HBeAg-negative patients (r= -0.291, P= 0.045). Decreased HBcrAg significantly correlated with reduced HBV DNA (r= 0.366, P= 0.001; r= 0.626, P < 0.001) and HBsAg (r = 0.526, P = 0.001; r = 0.289, P = 0.044) in HBeAg-positive and -negative patients, respectively, and with reduced HAI in HBeAg-positive patients (r = 0.329, P = 0.001). Patients with HBeAg loss (n = 29) showed a larger reduction in HBcrAg than those without (median 2.3 vs. 1.3 log10 U/mL, P = 0.001). In multivariate analysis, decreased HBcrAg was an independent predictor of HBeAg loss (P = 0.005).Conclusions:HBcrAg reflects viral replication and protein production. Decreased HBcrAg could predict HBeAg loss after antiviral therapy.Trial registration:Clinical Trials.gov: NCT01962155; https://www.clinicaltrials.gov/ct2/show/NCT01962155?term=NCT01962155&draw=2&rank=1